References
- Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756–1770.
- Cabriada JL, Domenech E, Gomollon F, et al. [Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease]. Gastroenterol Hepatol. 2006;29:85–92.
- Saez-Gonzalez E, Moret I, Alvarez-Sotomayor D, et al. Immunological mechanisms of adsorptive cytapheresis in inflammatory bowel disease. Dig Dis Sci. 2017;62:1417–1425.
- Danese S, Fiorino G, Reinisch W. Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther. 2011;34:1–10.
- Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–767.
- Gisbert JP, Marin AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41:613–623.
- Gonzalez Carro P, Perez Roldan F, Roncero Garcia Escribano O, et al. Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn’s disease. J Clin Apher. 2006;21:249–251.
- Fukunaga K, Yokoyama Y, Kamikozuru K, et al. Selective depletion of peripheral granulocyte/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohn’s disease. J Clin Apheresis. 2010;25:226–228.
- Ozeki K, Tanida S, Mizoshita T, et al. Combination therapy with intensive granulocyte and monocyte adsorptive apheresis plus adalimumab: therapeutic outcomes in 5 cases with refractory Crohn’s disease. Case Rep Gastroenterol. 2012;6:765–771.
- Ozeki K, Tanida S, Mizushima T, et al. Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis induced clinical remission in a Crohn’s disease patient with the loss of response to scheduled adalimumab maintenance therapy: a case report. Intern Med. 2012;51:595–599.
- Tanida S, Mizoshita T, Nishie H, et al. Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis. J Clin Med Res. 2015;7:884–889.
- Yokoyama Y, Kamikozuru K, Watanabe K, et al. Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte/monocyte apheresis: a case series. Cytokine. 2018;103:25–28.
- Rodriguez-Lago I, Gomez-Irwin L, Fernandez E, et al. Granulocyte-monocyte apheresis as an adjuvant therapy to anti-tumor necrosis factor drugs for ulcerative colitis. Ther Apher Dial. 2017;21:26–30.
- Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104:2990–2995.